INTRODUCTION {#sec1-1}
============

Osteoarthritis (OA) is a common, chronic, degenerative joint disorder characterized by joint pain, tenderness, limitation of movements, crepitus, occasional effusion, and variable degrees of local inflammation, without systemic manifestations.\[[@ref1][@ref2]\] The high prevalence rate, economic burden, and adverse implications on the quality of life make OA a major public health issue.\[[@ref3][@ref4]\] The hypoxic conditions, elevation in the activities of proteolytic enzymes, biochemical stress, genetic factors, and trauma are main causes of OA. Obesity is a major risk factor for the disease affecting the knee.\[[@ref1][@ref4]--[@ref6]\]

Currently, though pharmacological, mechanical, and surgical interventions are used, there is no known cure for OA.\[[@ref7]--[@ref9]\] Herbal remedies are widely used all over the world to treat the OA. Anti-arthritic herbs described in the Indian system of medicine are being used effectively in the management of the OA. Many permutations and combinations of the herbs mentioned in the classical texts of Indian system of medicine have been made and the formulations are being promoted as effective and safe remedies for the management of OA. Revalidation of the efficacy and safety of these formulations through clinical trials is a need of the hour.\[[@ref10]\]

"TLPL/AY/03/2008" is an Ayurvedic proprietary polyherbal formulation, developed and manufactured by Tulip Lab Private Limited, India in capsule dosage form. The drug is approved by Food and Drug Administration, State of Maharashtra, India. All the herbs present in the formulation are being used for the treatment of OA since thousands of years. Anti-arthritic potential of individual herbs present in the formulation has been documented in many scientific studies.\[[@ref11]--[@ref26]\] The compositions of the drug are given in [Table 1](#T1){ref-type="table"}.

###### 

Composition of investigational drug, i.e., 'TLPL/AY/03/2008' (each capsule contains extracts)

![](JAIM-4-33-g001)

In acute oral toxicity study performed as per the Organization for Economic Co-operation and Development (OECD) guidelines for the testing of chemicals, "TLPL/AY/03/2008" was non-toxic up to and at 2000 mg/kg body weight and can be classified as globally harmonized system (GHS) category 5/unclassified according to the GHS for classification of chemicals. In repeated dose 90-day toxicity study, no observed adverse effect level of 'TLPL/AY/03/2008' when administered orally to Sprague Dawley rats for 90 consecutive days was found in 500 mg/kg body weight in males and 1000 mg/kg body weight in females. Based on the data available on "TLPL/AY/03/2008," a hypothesis was made that the drug is effective and safe in the treatment of OA. To test the hypothesis, the present clinical study was conducted.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design {#sec2-1}
------------

It was an open label, non-comparative, prospective, clinical study. The study protocol and related documents were reviewed and approved by institutional ethics committee at center for rheumatic diseases, 11, Hermes Elegance, 1988 Convent Street, Camp, Pune - 411 001, India. The study was conducted in accordance with Schedule "Y" of Drugs and Cosmetics Act, India, amended in 2005 and Indian Council of Medical Research (ICMR) ethical guidelines for biomedical research on human participants, adopted from World Medical Association (WMA)-Declaration of Helsinki.

Primary and secondary outcome measures {#sec2-2}
--------------------------------------

Primary outcome measures of study were to evaluate efficacy of 'TLPL/AY/03/2008' in patients suffering from OA of knee by assessing knee joint pain on 100 mm visual analogue scale (VAS), average change from baseline to the end of therapy visit using WOMAC pain sub-scale score, WOMAC physical function sub-scale score, and WOMAC stiffness sub-scale score. The secondary outcome measures were to evaluate the efficacy of 'TLPL/AY/03/2008' in patients with OA of the knee by assessing changes in the swelling of knee joint, global assessment for overall improvement by the physician and by the patient, and also to assess the safety of the drug on clinical as well as laboratory parameters such as liver function tests (LFT), renal function tests (RFT), lipid profile, Complete blood count (CBC), Erythrocyte sedimentation rate (ESR), Hemoglobin (Hb)%, and urine examinations.

Sample size {#sec2-3}
-----------

The sample size calculation was based on the assumption that there will be decrease of 18.5% in Total WOMAC score from baseline to end of treatment. A sample size of 32 evaluable cases would provide an 80% power to estimate the reduction of total WOMAC score at 5% level of significance at the end of the study. Anticipating 25% dropouts, we enrolled 40 subjects to get 32 evaluable cases at the end of the study.

Inclusion criteria {#sec2-4}
------------------

Subjects of both sexes of age group between 40 years and 70 years (both inclusive), having symptoms of OA for minimum 6 months and maximum 5 years (confirmed by radiographs and diagnosed as per American college of rheumatology (ACR) diagnostic Criteria for OA of the knee), and subjects without any knee joint deformity and having VAS pain score ≥40 mm on weight bearing activities were included in the study. All the patients included in the study were allowed to take paracetamol up to 2 g/day as a rescue medication in case of severe joint pain.

Exclusion criteria {#sec2-5}
------------------

The patients having rheumatoid arthritis, gout, pseudo-gout, inflammatory arthritis, Paget\'s disease of bone, chronic pain syndrome, fibromyalgia, other major joint disorders, and patients having history of arthroscopy or major trauma to the joint in the previous 6 months before the screening visit were not included in the study. Patients requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index knee joint during the study were excluded. The patients with signs of clinically important active inflammation of knee joint at the screening visit and/or baseline visits were excluded. Patients taking any other investigational drug were not included in the study. The patients who were on systemic corticosteroids for past 2 months from screening visit or patients who used intra-articular visco-supplementation for the past 3 months from screening visit were excluded. The patients having major diseases, pregnant and lactating mothers, and persons having known hypersensitivity to ingredients used in study drug were excluded.

Study procedures {#sec2-6}
----------------

On screening visit, patient\'s voluntary written informed consent was taken and general and systemic examinations were done. Patient\'s blood and urine samples were collected and sent to the laboratory for investigations viz., CBC, Hb%, ESR, Random Blood Sugar level, Rheumatoid factor, Anti-streptolysin O (ASO) Titer, C-reactive protein (CRP), Serum Calcium, RFTs, LFTs, Lipid Profile, Urine examination, HIV-I and II, and Urine Pregnancy Test (in Female Subjects). The diagnosis of OA knee joint was confirmed by clinical evaluation and radiographs of knee joint (ACR diagnostic Criteria for diagnosis of OA Knee).\[[@ref27]\] Wash out period of 3 days was given and during wash out period and the entire study period, all patients were advised to refrain from Non-steroidal anti-inflammatory drugs (NSAIDs) or any other topical or systemic analgesics (except paracetamol up to 2 g/day).

On baseline visit, 40 patients were enrolled, who met the inclusion and exclusion criteria. All enrolled subjects were assigned in a single group and were given 'TLPL/AY/03/2008' a polyherbal formulation in a dose of 2 capsules twice daily orally after meals for 180 days. Recruited patients were advised to carry on their daily activities and exercises that they had been doing before the enrollment and also advised to continue the same till the end of study period. Patient\'s pain (preceding 48 h during weight bearing activities) was recorded on 100 mm VAS. WOMAC Index (Version Likert 3.0) containing 24 questions (Q) was used to grade pain (Q. 1-5), stiffness (Q. 6-7), and physical function difficulty (Q. 8-24) pertaining to the knee joint. The patient\'s answers were graded on a quantitative scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The maximum possible WOMAC score was 96 (pain = 20, stiffness = 8, and difficulty = 68). The source WOMAC was modified for Indian use and validated primarily through a consensual approach and pilot testing in the community and patients before this trial by the principal investigator. The knees were examined for the swelling/synovitis (grades: 0 = none, 1 = detectable synovial thickening without loss of bony contours, 2 = synovial thickening with loss of bony contours, and 3 = bulging synovial proliferation with cystic characteristics). On base line visit and on every follow-up visit (except 6^th^ visit), patients were provided with two containers each containing 70 Capsules of 'TLPL/AY/03/2008' for 1-month duration (120 capsules for 30 days and 20 additional capsules for delayed follow-up, maximum by 5 days). Patients were advised to return empty containers on every follow-up visit in order to check drug compliance.

Follow-up assessment {#sec2-7}
--------------------

Patients were called for follow-up visits on day 30 (Visit 1), day 60 (Visit 2), day 90 (Visit 3), day 120 (Visit 4), day 150 (Visit 5), and day 180 (Visit 6). On each follow-up visit, patient\'s general and systemic physical examinations were done. Assessment of the symptoms of OA was done on VAS and WOMAC OA index. Global assessment of overall efficacy of the study treatment was also done by the investigator and by the patient on every follow-up visit. Laboratory investigations (CBC, Hb%, ESR, RFTs, LFTs, Lipid Profile, and Urine examination) were repeated on 3^rd^ and 6^th^ visits. Drug tolerability was assessed by the patient and by the investigator on day 180.

Statistical analysis {#sec2-8}
--------------------

Consultant statistician performed the analysis of the data using statistical software SPSS 10.0. Data describing quantitative measures are expressed as median or mean ± SD or SE or the mean with range. Qualitative variables are presented as counts and percentage. Comparison of variables representing categorical data was performed using Chi-square test. All *P* values are reported based on two-sided significance test and all the statistical tests are interpreted at 5% level of significance.

RESULTS {#sec1-3}
=======

Out of 40 patients included in the study, 11 (27.5%) were males, whereas 29 (72.5%) were females. The mean age of patients was 57. 35 ± 10.58 years. Out of 40 recruited patients, 36 completed the study, whereas 4 subjects dropped out prematurely due to their personal reasons (other than the adverse events). All the 36 patients, who completed the study, had shown good compliance to the study medicine.

No significant change from baseline to end of therapy values in any of the vital signs (pulse rate, body temperature, respiratory rate, and systolic and diastolic blood pressure), appetite, and body weight was observed. At the end of the treatment (180 days), a statistically significant improvement in the sleep pattern was observed; all the patients had sound sleep.

At baseline visit, the mean knee joint pain score assessed on VAS was 51.89 ± 07.85. The mean knee joint pain score (VAS) reduced significantly from baseline to 43.71 ± 09.06 (15.8%) after 1-month treatment with "TLPL/AY/03/2008." The mean pain score further reduced significantly from baseline to 38.14 ± 08.60 (26.5%), 35.22 ± 10.71 (32.12%), 31.25 ± 11.47 (39.77%), and 24.79 ± 09.86 (52.22%) on days 60, 90, 120, and 150, respectively. At the end of the treatment, the mean knee joint pain score reduced significantly from baseline to 20.83 ± 08.35 (59.85%) \[[Figure 1](#F1){ref-type="fig"}\].

![Changes in the mean knee joint pain assessed on visual analogue scale](JAIM-4-33-g002){#F1}

At baseline visit, the mean WOMAC combined score was 35.38 ± 11.21, which was reduced significantly to 13.56 ± 06.89 (61.67%) at end of the study. The mean WOMAC pain sub-score reduced significantly from baseline value 08.56 ± 02.78 to 03.13 ± 01.96 (63.43%) at the end of the study. The mean WOMAC stiffness sub-scores reduced significantly from baseline value 02.81 ± 01.72 to 00.75 ± 00.77 (73.3%) at the end of the study. At baseline visit, the mean WOMAC difficulty sub-score was 24.00 ± 08.3, which was reduced significantly from baseline value to 09.69 ± 04.78 (59.6%) at the end of the study \[Figures [2](#F2){ref-type="fig"}-[5](#F5){ref-type="fig"}\].

![Changes in the mean WOMAC combined score](JAIM-4-33-g003){#F2}

![Changes in the mean WOMAC Pain sub-score](JAIM-4-33-g004){#F3}

![Changes in the mean WOMAC Stiffness sub-score](JAIM-4-33-g005){#F4}

![Changes in the mean WOMAC difficulty sub-score](JAIM-4-33-g006){#F5}

At baseline visit, the mean time taken by the patients to walk 50 feet was 16.31 ± 01.70 s. The mean time to walk 50 feet was reduced significantly from baseline value to 12.19 ± 02.04 (25.26%) s at the end of the study \[[Figure 6](#F6){ref-type="fig"}\].

![Changes in the mean time (s) taken to walk 50 feet distance](JAIM-4-33-g007){#F6}

At baseline visit, 19 (52.8%) out of 36 patients used paracetamol as rescue medicine for pain management. From day 120 onwards till the end of the study, no single subject used paracetamol as a rescue medication \[[Table 2](#T2){ref-type="table"}\].

###### 

Assessment of the rescue medication (paracetamol) used (*n* = 36)

![](JAIM-4-33-g008)

As per the global assessment for overall improvement done by the physician, 18 (50%) patients had good improvement, whereas 18 (50%) patients had satisfactory improvement at the end of the study. As per the global assessment for overall improvement done by the patient, 23 (63.9%) patients had good improvement, whereas 13 (36.1%) patients had satisfactory improvement at the end of the study.

As per the global assessment of drug tolerability done by the physician, no adverse events (Excellent tolerability) were reported in 29 (80.5%) patients \[[Table 3](#T3){ref-type="table"}\].

###### 

Global assessment of drug tolerability done by the physician and by the patient

![](JAIM-4-33-g009)

Adverse effects {#sec2-9}
---------------

As per the global assessment of drug tolerability done by the patient, no adverse events were reported in 27 (75%) patients, mild adverse events were reported in 8 (22.2%) patients such as insomnia, proctitis, reduced appetite, which subsided without medication, and one patient (2.8%) had experienced mild to moderate adverse event (mouth ulcer), which subsided with medication and did not necessitate stoppage of study medication. According to the study physician, casual relationship between adverse events and the study drug was not established.

At baseline visit, the mean value of total cholesterol in study patients was 147.31 ± 33.69, which was increased significantly to 191.72 ± 49.93 at the end of the study. The mean low density lipoprotein (LDL) cholesterol value at baseline was 74.89 ± 34.71, which was also increased significantly to 115.64 ± 24.65 at the end of the study. The mean very low density lipoprotein (VLDL) value at baseline was 26.56 ± 11.84, which was increased to 31.19 ± 9.45 (statistically not significant) at the end of the study. Though there was increase in total cholesterol, LDL, and VLDL values after treatment, the increased values at the end of the treatment were within normal limits (clinically insignificant).

The mean serum alkaline phosphate value at the beginning of the trial was 148.97 ± 53.15, which was increased significantly to 189.25 ± 61.03 at the end of the study. After 1 month post-study period, the value again came down to 156.85 ± 53.35. No significant changes in rest of the safety laboratory investigations were observed at the end of the study.

DISCUSSION {#sec1-4}
==========

In this clinical study, 6-month treatment with 'TLPL/AY/03/2008' significantly decreased the mean joint pain score (assessed on VAS). On day 90, slight increase in WOMAC combined score, all the three WOMAC sub-scales, and 50 feet walking time were observed from last follow-up visit (i.e., day 60), but when compared to baseline values, these values reduced on day 90. At the end of the study, WOMAC combined score, all the three WOMAC sub-scales, and 50 feet walking time decreased significantly from their baseline values. We are unable to explain the slight increase in these scores on day 90. A detailed experimental study can be planned to know the precise reason behind it.

The need of rescue medicine for pain management was reduced as study progressed. These findings highlighted that 'TLPL/AY/03/2008' reduced joint pain and joint stiffness and improved physical function in patients suffering from OA knee. Most of the patients had shown good overall improvement as per the assessment of the overall improvement done by the physician and by patient himself/herself. No patient reported the worsening of any sign or symptom of the OA knee during and at the end of the study.

The results of this clinical study are in line with the results of the earlier clinical studies conducted on Ayurvedic Proprietary Medicines for various types of OA more or less similar (with respect to the ingredients used in the formulation) to "TLPL/AY/03/2008".\[[@ref10]--[@ref11][@ref28]--[@ref32]\] The formulation 'TLPL/AY/03/2008' was developed by Tulip Lab Private Limited, containing seven herbal ingredients, which are being used since antiquity for the treatment of various types of arthritis. The formulation was developed keeping in mind that synergistic action of the seven ingredients will lead to a better formulation for the management of arthritis. Majority of the ingredients in 'TLPL/AY/03/2008' have anti-inflammatory and analgesic activities.\[[@ref11]--[@ref18][@ref20]--[@ref21][@ref23][@ref33]\] Plants such as Nyctanthes arbortristris, Withania somnifera, and Boswellia serrata possess immunomodulatory activity.\[[@ref14][@ref23]--[@ref24]\] Plants also reported anti-oxidant activity,\[[@ref18][@ref20][@ref25]\] chondoprotective activity,\[[@ref25][@ref34]\] and anti-pyretic activity.\[[@ref20]\] It was observed from results of this clinical study that the synergistic effect of the herbs present in the formulation has contributed to the overall anti-inflammatory and analgesic activities of the formulation "TLPL/AY/03/2008".

In acute and sub-chronic (90 days) toxicity studies, we demonstrated that 'TLPL/AY/03/2008' is safe and non-toxic in rats. In this clinical study, according to the global assessment of drug tolerability assessed by the physician, 97.2% subjects had feeling of good to excellent tolerability of drug, whereas 2.8% of the subjects had fair tolerability. The similar outcomes, as that of global assessment of tolerability assessed by the physician, were observed by subjects also. One subject had proctitis which was mild to moderate in nature and resolved after treatment. Mild to moderate mouth ulcer was observed in one subject, which also resolved after treatment. A significant increase over baseline to end of the study value was observed in safety laboratory parameters, such as serum alkaline phosphatase, total cholesterol, LDL cholesterol, and VLDL. Though there was significant increase in the above-mentioned values post-treatment, the increased values were within normal limits. To check whether the increase in the serum alkaline phosphatase continues even after the stoppage of the treatment, we performed serum alkaline phosphatase in most of the cases 1 month after discontinuation of the treatment. It was observed that serum alkaline phosphatase value came down near to its baseline value. Taken together, these observations further demonstrate that 'TLPL/AY/03/2008' is safe in the treatment of OA in humans.

It is evident from the data that total cholesterol, LDL, VLDL, and serum alkaline phosphatase values increased at the end of the study treatment. After reviewing literature on the individual ingredient of the formulation, it is observed that most of the ingredients possess hypolipidemic activity. Also majority of the herbs present in the formulation have hepatoprotective activity. In spite of having hypolipidemic and hepatoprotective herbs in the formulation, post-treatment increase in TC, LDL, VLDL, and serum alkaline phosphatase values cannot be explained with the available data. Clinical studies in large population and experimental studies on the formulation are needed to find out the suitable answers for the same. This study also lacks in ruling out the "placebo effect."

The sample size on which the drug has been tested though enough to show statistically significant effect, but a randomized, double blind, multi-centric clinical study with large sample size to evaluate the efficacy and safety of 'TLPL/AY/03/2008' is indicated.

CONCLUSION {#sec1-5}
==========

In summary, this study provides the evidence in support of the potential efficacy and safety of the herbal formulation 'TLPL/AY/03/2008' in subjects suffering from OA of knee. Six months of treatment with 'TLPL/AY/03/2008' significantly reduced joint pain, improved joint function and mobility in subjects suffering from OA knee. Hence, it can be concluded that the 'TLPL/AY/03/2008' is a safe and effective for treatment of OA.
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